LinkedIn Profile

Access ChipDX LLC historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Sector Industry
private:chipdxllc-2 1559734 May 23rd, 2019 12:00AM ChipDX LLC 20 0.00 Open Medical Devices May 23rd, 2019 01:34PM May 23rd, 2019 01:34PM ChipDX develops and delivers novel multi-gene diagnostic and prognostic assays for oncology. The aim of the company is to increase access to advanced, well-validated predictive and prognostic assays, through collaborations with existing diagnostic service providers and also through our modular, online delivery system: www.ChipDX.com Currently we have created tests for: - Assessing the quality of a patients genomic profile to ensure reliable, accurate results - Characterizing metastatic or poorly differentiated tumors, and - Predicting recurrence in patients diagnosed with early stage breast or colon cancer. Other novel assays are in active development and we are keen to form strategic collaborations with appropriate organizations and individuals to further validate and market those already developed. Related publications: Van Laar, R.K., An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Br J Cancer. Van Laar, R. K. (In Press). "Design and multi-series validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival." J Mol Diagn. Open Diagnostic assay development, Personalized medicine, Cancer prognosis prediction, Genomics Open PO Box 286874 New York NY US 10128 Health Care Equipment & Services Health Care
private:chipdxllc-2 1559734 Nov 7th, 2017 12:00AM ChipDX LLC 18 0.00 Open Medical Devices Nov 7th, 2017 06:26PM Nov 7th, 2017 06:26PM ChipDX develops and delivers novel multi-gene diagnostic and prognostic assays for oncology. The aim of the company is to increase access to advanced, well-validated predictive and prognostic assays, through collaborations with existing diagnostic service providers and also through our modular, online delivery system: www.ChipDX.com Currently we have created tests for: - Assessing the quality of a patients genomic profile to ensure reliable, accurate results - Characterizing metastatic or poorly differentiated tumors, and - Predicting recurrence in patients diagnosed with early stage breast or colon cancer. Other novel assays are in active development and we are keen to form strategic collaborations with appropriate organizations and individuals to further validate and market those already developed. Related publications: Van Laar, R.K., An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Br J Cancer. Van Laar, R. K. (In Press). "Design and multi-series validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival." J Mol Diagn. Health Care Equipment & Services Health Care
private:chipdxllc-2 1559734 Nov 1st, 2017 12:00AM ChipDX LLC 18 0.00 Open Medical Devices Nov 1st, 2017 06:01AM Nov 1st, 2017 06:01AM ChipDX develops and delivers novel multi-gene diagnostic and prognostic assays for oncology. The aim of the company is to increase access to advanced, well-validated predictive and prognostic assays, through collaborations with existing diagnostic service providers and also through our modular, online delivery system: www.ChipDX.com Currently we have created tests for: - Assessing the quality of a patients genomic profile to ensure reliable, accurate results - Characterizing metastatic or poorly differentiated tumors, and - Predicting recurrence in patients diagnosed with early stage breast or colon cancer. Other novel assays are in active development and we are keen to form strategic collaborations with appropriate organizations and individuals to further validate and market those already developed. Related publications: Van Laar, R.K., An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Br J Cancer. Van Laar, R. K. (In Press). "Design and multi-series validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival." J Mol Diagn. Health Care Equipment & Services Health Care
private:chipdxllc-2 1559734 May 23rd, 2019 12:00AM ChipDX LLC 20 0.00 Open Medical Devices May 23rd, 2019 01:34PM May 23rd, 2019 01:34PM ChipDX develops and delivers novel multi-gene diagnostic and prognostic assays for oncology. The aim of the company is to increase access to advanced, well-validated predictive and prognostic assays, through collaborations with existing diagnostic service providers and also through our modular, online delivery system: www.ChipDX.com Currently we have created tests for: - Assessing the quality of a patients genomic profile to ensure reliable, accurate results - Characterizing metastatic or poorly differentiated tumors, and - Predicting recurrence in patients diagnosed with early stage breast or colon cancer. Other novel assays are in active development and we are keen to form strategic collaborations with appropriate organizations and individuals to further validate and market those already developed. Related publications: Van Laar, R.K., An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Br J Cancer. Van Laar, R. K. (In Press). "Design and multi-series validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival." J Mol Diagn. Open Diagnostic assay development, Personalized medicine, Cancer prognosis prediction, Genomics Open PO Box 286874 New York NY US 10128 Health Care Equipment & Services Health Care
private:chipdxllc-2 1559734 Nov 7th, 2017 12:00AM ChipDX LLC 18 0.00 Open Medical Devices Nov 7th, 2017 06:26PM Nov 7th, 2017 06:26PM ChipDX develops and delivers novel multi-gene diagnostic and prognostic assays for oncology. The aim of the company is to increase access to advanced, well-validated predictive and prognostic assays, through collaborations with existing diagnostic service providers and also through our modular, online delivery system: www.ChipDX.com Currently we have created tests for: - Assessing the quality of a patients genomic profile to ensure reliable, accurate results - Characterizing metastatic or poorly differentiated tumors, and - Predicting recurrence in patients diagnosed with early stage breast or colon cancer. Other novel assays are in active development and we are keen to form strategic collaborations with appropriate organizations and individuals to further validate and market those already developed. Related publications: Van Laar, R.K., An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Br J Cancer. Van Laar, R. K. (In Press). "Design and multi-series validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival." J Mol Diagn. Health Care Equipment & Services Health Care
private:chipdxllc-2 1559734 Nov 1st, 2017 12:00AM ChipDX LLC 18 0.00 Open Medical Devices Nov 1st, 2017 06:01AM Nov 1st, 2017 06:01AM ChipDX develops and delivers novel multi-gene diagnostic and prognostic assays for oncology. The aim of the company is to increase access to advanced, well-validated predictive and prognostic assays, through collaborations with existing diagnostic service providers and also through our modular, online delivery system: www.ChipDX.com Currently we have created tests for: - Assessing the quality of a patients genomic profile to ensure reliable, accurate results - Characterizing metastatic or poorly differentiated tumors, and - Predicting recurrence in patients diagnosed with early stage breast or colon cancer. Other novel assays are in active development and we are keen to form strategic collaborations with appropriate organizations and individuals to further validate and market those already developed. Related publications: Van Laar, R.K., An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Br J Cancer. Van Laar, R. K. (In Press). "Design and multi-series validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival." J Mol Diagn. Health Care Equipment & Services Health Care

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.